Eupraxia Pharmaceuticals (EPRX) financial statements
Eupraxia Pharmaceuticals reported revenue of $0 in fiscal 2025.
Net income was -$39M.
The diluted share count rose 107% over the period (dilution).
Income statement
Fiscal years, from Eupraxia Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 |
| Research and development | $14M | $20M | $16M | $21M |
| Selling, general and admin | $4M | $7M | $11M | $17M |
| Interest expense | $982,856 | $1M | $603,573 | $0 |
| Pre-tax income | -$19M | -$29M | -$26M | -$39M |
| Income tax | $0 | $36,423 | $1,804 | $19,091 |
| Net income | -$18M | -$28M | -$26M | -$39M |
| EPS (diluted) | -$0.96 | -$1.17 | -$0.76 | -$1.03 |
| Diluted shares | 19M | 24M | 34M | 40M |
Balance sheet
Fiscal years, from Eupraxia Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Cash and short-term investments | $18M | $19M | $33M | $81M |
| Receivables | — | $153,749 | $258,074 | $716,095 |
| Total current assets | $19M | $20M | $34M | $85M |
| Property, plant and equipment | $443,464 | $409,587 | $357,893 | $834,429 |
| Total assets | $19M | $20M | $35M | $86M |
| Total current liabilities | $3M | $19M | $3M | $6M |
| Total liabilities | $12M | $19M | $3M | $6M |
| Shareholders' equity | $8M | $2M | $33M | $82M |
| Net debt | -$18M | -$19M | -$33M | -$81M |
Cash flow
Fiscal years, from Eupraxia Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -$14M | -$21M | -$30M | -$29M |
| Stock-based compensation | $1M | $1M | $3M | $9M |
| Net borrowing | -$74,845 | -$79,441 | -$62,651 | $0 |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for EPRX.
Open EPRX in InvestinglyQuestions
What was Eupraxia Pharmaceuticals's revenue in 2025?
$0 in fiscal 2025, from its 10-K filing.
From Eupraxia Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.